alpha 1A adrenergic receptor Agonists
4 drugsAbout alpha 1A adrenergic receptor
The alpha 1A adrenergic receptor (α1A-AR) is a G protein-coupled receptor activated by catecholamines like norepinephrine and epinephrine. It mediates smooth muscle contraction and plays a role in various physiological processes.
The α1A-AR is a drug target, but there is currently no genetic evidence directly linking it to specific diseases. Its role in smooth muscle contraction makes it a valuable target for pharmacological intervention.
Two FDA-approved drugs target the α1A-AR: tamsulosin hydrochloride and silodosin. Both drugs are small molecules and are classified within the 'other' therapeutic area.
Top alpha 1A adrenergic receptor Drugs
Novartis and PRINSTON INC are the companies with approved drugs targeting alpha 1A adrenergic receptor.
The market is concentrated, so new entrants need a strong value proposition to compete.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| CARDURA XL | Viatris | 2005 | 1 |
alpha 1A adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
alpha 1A adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
alpha 1A adrenergic receptor Clinical Trials 124 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 1A adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 20 | 0 | 1 | 100% |
| Phase 2 | 24 | 15 | 1 | 7 | 94% |
| Phase 3 | 28 | 15 | 7 | 6 | 68% |
| Phase 4 | 51 | 33 | 6 | 12 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1A adrenergic receptor Drug Approval Timeline (2005 - 2017)
The first drug was approved in 2010, and the most recent in 2017, spanning 8 years.
The approval timeline suggests a potentially maturing market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 84 (22 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 1A adrenergic receptor. A trial counts if an approved drug acting on alpha 1A adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.